1. Smiseth O.A., Tendera M. (Eds.) Diastolic heart failure. - London: Springer-Verlag London Limited, 2008. - 349 p.
2. Mottaram P.M., Marwick T.H. Assessment of diastolic function: what the general cardiologist needs to know // Heart. - 2005. - Vol. 91, № 5. - P. 681-695.
3. Mark D.B., Felker G.M. B-type natriuretic peptide - a biomarker for all seasons? // N. Engl. J. Med. - 2004. - Vol. 350, № 7. - P. 718-720.
4. McCullough P.A., Nowak R.M., McCord J. et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study // Circulation. - 2002. - Vol. 106, № 4. - P. 416-422.
5. Maisel A.S., McCord J., Nowak R.M. et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study // J. Am. Coll. Cardiol. - 2003. - Vol. 41, № 11. - P. 2010-2017.
6. Dokainish H., Zoghbi W.A., Al-Bakshy F.A., Dhir M., Quinones M.A., Nagueh S.F. Optimal noninvasive assessment of LV filling pressures: a comparison of tissue Doppler echocardiography and BNP in patients with pulmonary artery catheters // Circulation. - 2004. - Vol. 109, № 20. - P. 2432-2439.
7. Yamamoto K., Burnett J.C., Jougasaki M. et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy // Hypertension. - 1996. - Vol. 28, № 6. - P. 988-994.
8. Wright S.P., Prickett T.C.R., Doughty R.N., Frampton C., Greg D. Amino-terminal pro-C-type natriuretic peptide in heart failure // Hypertension. - 2004. - Vol. 43, № 1. - P. 94-100.
9. Luchner A., Hengstenberg C., Löwel H., Riegger G.A., Schunkert H., Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP // Hypertension. - 2005. - Vol. 46, № 1. - P. 118-123.
10. Wang T.J., Larson M.G., Levy D., Benjamin E.J. et al. Impact of obesity on plasma natriuretic peptide levels // Circulation. - 2004. - Vol. 109, № 5. - P. 594-600.
11. Das S.R., Drazner M.H., Dries D.L. et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study // Circulation. - 2005. - Vol. 112, № 4. - P. 2163-2168.
12. Bibbins-Domingo K., Ansari M., Schiller N.B., Massie B., Whooley M.A. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study // Circulation. - 2003. - Vol. 108, № 24. - P. 2987-2992.
13. Lubien E., DeMaria A., Krishnaswamy K. Utility of B-natriuretic peptide in diagnosing diastolic dysfunction // Circulation. - 2002. - Vol. 105, № 5. - P. 595-601.
14. Senni M., Tribouilloy C.M., Rodeheffer R.J. et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991 // Circulation. - 1998. - Vol. 98, № 21. - P. 2282-2289.
15. Lukowicz T.V., Fischer M., Hense H.W. et al. BNP as a marker of diastolic dysfunction in the general population: Importance of left ventricular hypertrophy // Eur. J. Heart Fail. - 2005. - Vol. 7, № 4. - P. 525-531.
16. Tschope C., Kasner M., Westermann D. et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements // Eur. Heart J. - 2005. - Vol. 26, № 21. - P. 2277-2284.
17. Yamaguchi H., Yoshida J., Yamamoto K. et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy // J. Am. Coll. Cardiol. - 2004. - Vol. 43, № 1. - P. 55-60.
18. Rousseau M.F., Gurne O., Duprez D. et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy // J. Am. Coll. Cardiol. - 2002. - Vol. 40, № 9. - P. 1596-1601.
19. Latini R., Masson S., Anand I. et al. Valsartan Heart Failure Trial Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT) // Circulation. - 2002. - Vol. 106, № 19. - P. 2454-2458.
20. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 // Eur. Heart J. - 2008. - Vol. 29, № 19. - P. 2388-2442.
21. Национальные клинические рекомендации // Сб. под ред. Р.Г. Оганова. - 2-е изд. - М.: Изд-во «Силицея-Полиграф», 2009. - 528 с.
22. Lok D.J., Van Der Meer P., de la Porte P.W. et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study // Clin. Res. Cardiol. - 2010. - Vol. 99, № 5. - P. 323-328.
23. Felker G.M., Fiuzat M., Shaw L.K. et al. Prognostic value of galectin-3 in chronic heart failure: results from the HF-ACTION study // Eur. Heart J. - 2010. - Vol. 31, № 1. - P. 429.
24. Jaarsma T., van der Wal M.H., Leesman-Leegte I. et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure // Arch. Intern. Med. - 2008. - Vol. 168, № 3. - P. 316-324.
25. Lin Y.H., Lin L.Y., Wu Y.W. et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients // Clin. Chim. Acta. - 2009. - Vol. 409, № 1-2. - P. 96-99.
